Rapid Micro Biosystems (RPID) Debt to Equity (2020 - 2026)

Rapid Micro Biosystems' (RPID) quarterly Debt to Equity came in at $0.93 in Q1 2026, up 64.09% quarter-over-quarter from $0.57 in Q4 2025.

Rapid Micro Biosystems (RPID) Debt to Equity (2020 - 2026) Analysis & Trends

Rapid Micro Biosystems has disclosed Debt to Equity across 4 years of filings, most recently posting $0.93 for Q1 2026.

Debt to Equity for Q1 2026 came in at $0.93, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $0.93 (changed N/A YoY), and the FY2025 annual result was $0.57, changed N/A from the prior year.
Debt to Equity came in at $0.93 for Q1 2026 at Rapid Micro Biosystems, up from $0.57 in the prior quarter.
In the past five years, Debt to Equity ranged from a high of $0.93 in Q1 2026 to a low of $0.42 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	0.65
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	0.64
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	0.57
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	0.42
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	0.06
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	0.71
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	0.95
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	0.27
10	Rapid Micro Biosystems	77.24 Mn	54.29 Mn	371,000.00	0.93

Download Data